Bio-techne CORP Form 4 insider transactions

Director John L. Higgins exercised stock options and disposed of shares of Bio-Techne Corp on September 12, 2024.

Kim Kelderman, CEO of Bio-Techne Corp, reports exercising stock options and discloses changes in beneficial ownership of company stock.

James Hippel, CFO of Bio-Techne Corp, filed a Form 4 detailing changes in his beneficial ownership, including the acquisition of restricted stock units and stock options.

CEO Kim Kelderman reports changes in beneficial ownership of Bio-Techne Corp shares, including stock options and restricted stock units, as per a Form 4 filing with the SEC.

William Geist, President of Protein Sciences at Bio-Techne Corp, filed a Form 4 detailing changes in his beneficial ownership of company stock and derivative securities.

Shane Bohnen, SVP General Counsel of Bio-Techne Corp, reports transactions involving common stock, stock options, and restricted stock units.

Matthew McManus, President DGS of Bio-Techne Corp, reports the acquisition of performance-based restricted stock units and stock options.

Robert V. Baumgartner, a director at Bio-Techne Corp, exercised stock options and sold 16,000 shares of common stock on August 8, 2024.

Bio-Techne CFO James Hippel exercised stock options and disposed of shares on August 2, 2024, according to a Form 4 filing with the SEC.

Kim Kelderman, CEO of Bio-Techne Corp, exercised stock options and disposed of shares on July 31, 2024, according to a Form 4 filing with the SEC.

James Hippel, CFO of Bio-Techne Corp, exercised stock options and disposed of shares to cover tax obligations, according to a Form 4 filing.

Director John L. Higgins exercised stock options and reported changes in beneficial ownership of Bio-Techne Corp shares.

Director John L. Higgins exercised stock options and sold 4,000 shares of Bio-Techne Corp common stock on May 14, 2024.

Director Judith V. Klimovsky reports acquisition of Bio-Techne Corp common stock and stock options.

Shane Bohnen, SVP General Counsel of Bio-Techne Corp, reports the acquisition and disposal of common stock and restricted stock units on April 3, 2024.

Roeland Nusse, a director at Bio-Techne Corp, sold 10,400 shares of common stock at a weighted average price of $76.9834 on March 7, 2024.